Press releases

16 September 2014, Amsterdam
Mirnext is a Dutch biomedical company focused on the discovery, validation and commercialization of miRNAs as novel biomarkers for cardiovascular disease. The company develops clinically actionable multi-marker tests to improve diagnostic routine and clinical management of heart failure. 
Read more
Bookmark and Share